Eli Lilly to Acquire Centessa Pharmaceuticals for Initial $6.3 Billion

Eli Lilly announced its intention to acquire Centessa Pharmaceuticals for an initial $6.3 billion, a deal confirmed by recent reports, aiming to bolster its portfolio of sleep medicines and narcolepsy drugs.

31 Mar, 11:52 — 31 Mar, 15:26

Post Share

Why this matters

This acquisition signifies Eli Lilly's strategic move to bolster its neuroscience pipeline, particularly in the lucrative and underserved area of sleep disorders like narcolepsy. It reflects the pharmaceutical industry's ongoing consolidation and pursuit of innovative drug candidates to drive future growth.

Key entitiesEli Lilly Centessa Pharmaceuticals

The Story

What 8 sources agree on, dispute, and miss

What sources agree on

Eli Lilly will acquire Centessa Pharmaceuticals.
The initial acquisition price is $6.3 billion.
The total deal value could reach up to $7.8 billion.
The acquisition aims to expand Eli Lilly's neuroscience portfolio, focusing on sleep disorder drugs.

Key claims3 agreed

✓

Eli Lilly will acquire Centessa Pharmaceuticals for an initial $6.3 billion.

agreed·YahooNYTwsj

✓

The total acquisition value for Centessa Pharmaceuticals could be up to $7.8 billion.

agreed·cnbcReutersmarketwatchbloomberg

✓

The acquisition will expand Eli Lilly's neuroscience portfolio.

agreed·YahooNYT

Coverage gaps

Centessa is one of several companies developing a new class of drugs for narcolepsy.

Reportedcnbc

MissingYahooNYTReuters+4

Eli Lilly is flush with cash from sales of its market-leading GLP-1 franchise and has been an active dealmaker.

Reportedmarketwatch

MissingYahooNYTcnbc+4

The acquisition is expected to close in the third quarter.

Reporteddie-presse

MissingYahoo

The Story

Analyzing sources…

Source Diversity

High (71/100)

8 sources33/33

Spectrum spread— 4/5 buckets covered25/33

Far L1

Far Left (1)

NYT

Left2

Left (2)

Yahoocnbc

Center3

Center (3)

Reutersmarketwatchbloomberg

Right2

Right (2)

die-pressewsj

Far R

Geographic diversity— 3 regions13/34

US6Intl1Austria1

Political spectrum

LeftCenterRight

nytimes

yahoo

cnbc

reuters

marketwatch

bloomberg

die-presse

wsj

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

NYTcenter-leftcenter-leftneutralMostly FactualStraightforward reporting on business transaction

Yahoocentercenter-leftneutralMostly FactualFactual reporting on corporate acquisition

Coverage leans: balanced

The coverage is largely neutral and factual, focusing on the financial details and strategic implications of the acquisition without significant political framing.

Sources

Showing 6 of 8 sources

ReutersVery High58d ago

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet - Reuters

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet Reuters

Read full article →

NYTMostly Factual58d ago

Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billion

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug.

By Rebecca Robbins

Read full article →

wsjHigh58d ago

Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion - WSJ

Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion WSJ

Read full article →

cnbcMostly Factual58d ago

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for people to stay awake.

Read full article →

marketwatchMostly Factual58d ago

Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug

The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.

By Jaimy Lee

Read full article →

YahooMostly Factual58d ago

Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio

Read full article →

Coverage Timeline

First report: bloomberg · 31 Mar, 11:22|Full coverage: 8 · 4h|Window: 4h

Left-leaningCenterRight-leaning

bloomberg31 Mar, 11:22First to report

Eli Lilly to Buy Centessa Pharmaceuticals for Up to $7.8 Billion - Bloomberg.com

wsj31 Mar, 11:52

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet - Reuters

2h later

cnbc31 Mar, 14:46

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

NYT31 Mar, 14:49

Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billion

Yahoo31 Mar, 15:26Latest update

Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio

Story evolution

Initial ReportingMarch 31 morning

Early reports confirm Eli Lilly's intent to acquire Centessa Pharmaceuticals for an initial $6.3 billion, with potential for up to $7.8 billion.

Strategic ContextMarch 31 afternoon

Later reports elaborate on the strategic rationale, highlighting the expansion of Eli Lilly's neuroscience portfolio and focus on sleep disorder drugs.

Eli Lilly to Acquire Centessa Pharmaceuticals for Initial $6.3 Billion

Why this matters

The Story

What sources agree on

Key claims3 agreed

Coverage gaps

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet - Reuters

Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billion

Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion - WSJ

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug

Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio

Coverage Timeline

Eli Lilly to Buy Centessa Pharmaceuticals for Up to $7.8 Billion - Bloomberg.com

Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion - WSJ

Eli Lilly übernimmt Schlafmittel-Firma Centessa für Milliarden

Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet - Reuters

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billion

Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio

Story evolution

Related Stories

Extreme Training: What Heat Training Does to the Body

Can store-bought potted herbs be freely eaten?

Parts of north Louth ‘like a third world country’ due to water outages during a heatwave

Scientists develop vitamin K-derived compounds that may help regenerate brain cells

Why this matters

Story evolution

The Story

What sources agree on

Key claims3 agreed

Coverage gaps

Coverage matrix

Political spectrum